home | news | 2017

June 15, 2017

Research highlights at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL

Among CPDR’s ASCO poster presentations, co-led by Dr. Jennifer Cullen, special attention was given to a study examining the importance of extent of PSA screening prior to prostate cancer diagnosis on adverse pathology at surgery and cancer progression.

Read OncologyAlerts.com News Release

ASCO 2017

Presenting this work, pictured above, are: Dr. Jennifer Cullen, Director, Epidemiology Research Program, CPDR & Associate Professor, USU, Dept of Surgery (left) and Dr. (CPT) Thomas Gerald, Urology Resident, Walter Reed National Military Medical Center (right).

Other CPDR research presented at this year’s ASCO meeting included:

  • Predictors of post -surgical race-specific prostate cancer progression (Cullen et al.)
  • PSA Doubling Time and Proximal PSA Value Predict Metastasis-Free Survival in Men with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Markowski et al.)
  • Association of risk of clinical recurrence and prostate cancer death with a 17-gene genomic prostate score value <20 (Febbo et al.)